IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
Cannabis Law Report
JUNE 7, 2021
The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. Securities and Exchange Commission (“SEC”) on July 13, 2020. About IGC: India Globalization Capital, Inc.
105 
Let's personalize your content